




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 223/16, 239/26 A61K 31/55		A1	(11) International Publication Number: <b>WO 93/03015</b> (43) International Publication Date: 18 February 1993 (18.02.93)
(21) International Application Number: PCT/US92/06538 (22) International Filing Date: 5 August 1992 (05.08.92)			(74) Agents: MCCARTHY, Mary, E. et al.; SmithKline Beecham Corporation, Corporate Patents - U.S. (UW2220), 709 Swedeland Road, P.O. Box 1538, King of Prussia, PA 19406-0939 (US).
(30) Priority data: 9116824.5 5 August 1991 (05.08.91) GB			(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; Corporate Patents - U.S. (UW2220), 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors; and (75) Inventors/Applicants (for US only) : DEMARINIS, Robert, Michael [US/US]; 128 Golf View Road, Ardmore, PA 19003 (US). PFEIFFER, Francis, Richard [US/US]; 201 Sussex Drive, Cinnaminson, NJ 08077 (US).			

(54) Title: HETEROALKOXY BENZAZEPINES



## (57) Abstract

Alpha-adrenergic receptor antagonists having formula (I) which are useful to produce  $\alpha$ -adrenoceptor antagonism, pharmaceutical compositions including these antagonists, and methods of using these antagonists to produce  $\alpha$ -adrenoceptor antagonism in mammals.

***FOR THE PURPOSES OF INFORMATION ONLY***

**Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.**

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

- 1 -

10

## HETEROALKOXY BENZAZEPINES

15

### FIELD OF THE INVENTION

This invention relates to novel substituted 2,3,4,5-tetrahydro-1H-3-benzazepine compounds having  $\alpha$ -adrenergic receptor antagonist activity.

20

### BACKGROUND OF THE INVENTION

The autonomic nervous system is separated into the cholinergic and adrenergic nervous systems.

25 Norepinephrine, the neurotransmitter of the adrenergic nervous system, exerts its activity by interaction with receptors (adrenoceptors) on the effector organs or on the nerve endings. The adrenoceptors are of two primary types:  $\alpha$  and  $\beta$ . Based upon selectivity of the receptors for a series of agonists and antagonists, the  $\alpha$  adrenoceptors have been subdivided into  $\alpha_1$  and  $\alpha_2$  subtypes.

30 A large amount of experimental evidence now supports the view that the  $\alpha_2$  subtype is a heterogeneous adrenoceptor class. (For a general review see Timmermans and Van Zwieten, J. Med. Chem., 25, 1389 (1982)).

35 Experiments using 6-chloro-9-(3-methyl-2-butenyloxy)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SK&F 104078) demonstrated that the classical adrenoceptors are heterogeneous and can be divided into SK&F 104078-insensitive and SK&F 104078-sensitive  $\alpha_2$  adrenoceptors. The latter variously are referred to as postjunctional  $\alpha_2$  adrenoceptors or, preferably,  $\alpha_3$  adrenoceptors, United States Patent No. 4,683,229, July 28, 1987.

As one of the primary regulators of peripheral vascular tone,  $\alpha$  adrenoceptors long have been the targets of efforts to develop agents effective in changing vascular tone for use in treating diseases, such as hypertension, in which alterations in vascular resistance produce therapeutic benefits. Antihypertensive compounds presently in clinical use that function via interaction with  $\alpha$  adrenoceptors include methyldopa, clonidine, and prazosin. Efforts to modulate sympathetic tone through interactions with  $\alpha$  adrenoceptors have resulted in several compounds that interact somewhat selectively with  $\alpha_1$  or  $\alpha_2$  adrenoreceptors. Selective agonists include phenylephrine and methoxamine which preferentially activate  $\alpha_1$  receptors; and clonidine,  $\alpha$ -methyl-norepinephrine, and tramazoline which preferentially activate  $\alpha_2$  adrenoceptors. Examples of selective  $\alpha$ -adrenoceptor antagonists include prazosin which has high selectivity for  $\alpha_1$  adrenoceptors; and the  $\alpha_2$ -selective blockers yohimbine and rauwolscine.

United States Patent No. 4,469,634, dated September 4, 1984, describes allyloxy- and allythio- 2,3,4,5-tetrahydro-1H-3-benzazepines useful as intermediates for preparing  $\alpha_2$  adrenoceptor affinity resins and as antihypertensive agents.

U.S. Patent No. 4,683,229 dated July 28, 1987, describes 6-halo-9-alkenyloxy-2,3,4,5-tetrahydro-1H-3-benzazepines having  $\alpha_3$ -selective antagonist activity.

U.S. Patent No. 4,265,890 dated May 5, 1981, describes mercapto substituted-2,3,4,5-tetrahydro-1H-3-benzazepines having dopamine receptor blocking activity.

30

#### SUMMARY OF THE INVENTION

The present invention resides in the discovery that certain substituted-2,3,4,5,-tetrahydro-1H-3-benzazepine compounds are  $\alpha$ -adrenoceptor antagonists. Presently preferred compounds of the invention include:

6-chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine,

6-chloro-9-(4-chloro-1H-pyrazol-1-ylmethoxy)-  
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-  
1-ylmethoxy)-1H-3-benzazepine,  
5 6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-  
methyl-1H-3-benzazepine,  
6-chloro-9-[3-(2-furanyl)-2-propenyloxy]-2,3,4,5-  
tetrahydro-3-methyl-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-  
10 thienylmethoxy)-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-  
thienylmethoxy)-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-  
pyrazol-1-yl)ethoxy]-1H-3-benzazepine,  
15 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-  
triazol-1-ylmethoxy)-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-  
pyridinylmethoxy)-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-  
20 triazol-1-yl)ethoxy]-1H-3-benzazepine,  
6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-  
methyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine,  
6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-  
25 carbonyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-  
yl)-1H-3-benzazepine,  
6-chloro-9-(2,5-dimethyl-1H-pyrrol-1-yl)-2,3,4,5-  
tetrahydro-3-methyl-1H-3-benzazepine,  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-  
30 ylmethyl)-1H-3-benzazepine,  
6-chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)propyl]-  
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine, and  
6-chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)pentyl]-  
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine; or a  
35 pharmaceutically acceptable salt thereof.  
The most preferred compound of the invention is 6-  
chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-

1H-3-benzazepine or a pharmaceutically acceptable salt thereof.

In a further aspect of the invention there are provided methods of antagonizing adrenoceptors in 5 mammals, including humans, that comprise administering internally to a subject an effective amount of a substituted 2,3,4,5-tetrahydro-1H-3-benzazepine compound.

Included in the present invention are pharmaceutical compositions comprising compounds useful in the method of 10 the invention and a suitable pharmaceutical carrier. Preferably, these compositions are used to produce a adrenoceptor antagonism and contain an effective amount of compounds useful in the methods of the invention.


15

DETAILED DESCRIPTION OF THE INVENTION

The presently invented compounds that are  $\alpha$ -adrenoceptor antagonists or are useful in preparing  $\alpha$ -adrenoceptor antagonists are represented by the following Formula (I):

20

(I)



25

in which:

X is H, Cl, Br, F, I,  $\text{CF}_3$ ,  $\text{C}_1\text{-6alkyl}$ ,  $\text{COR}^1$ ,  $\text{CO}_2\text{R}^2$ ,  $\text{CONR}^2\text{R}^2$ , CN,  $\text{NO}_2$ ,  $\text{NR}^3\text{R}^4$ ,  $\text{OR}^3$ ,  $\text{SR}^1$ ,  $\text{SCF}_3$ , or any accessible combination thereof up to three substituents;

30 R is H,  $\text{C}_1\text{-6alkyl}$ , or  $\text{C}_3\text{-5alkenyl}$ ;

A is  $-\text{OCO}(\text{CH}_2)_{1-4}-$ ,  $-\text{OCH}_2\text{CH}=\text{CH}-$ ,  $-\text{CO}_2(\text{CH}_2)_{1-4}-$ ,  $-(\text{CH}_2)_{0-6}-$ , or  $-(\text{CH}_2)_n\text{Z}(\text{CH}_2)_m-$ , wherein n is 0-4 and m is 1-5, with the proviso that m and n taken together are no greater than 5;

35 Z is O or S;

each  $\text{R}^1$  independently is  $\text{C}_1\text{-6alkyl}$  or  $(\text{CH}_2)_{0-6}\text{phenyl}$ ;

each R<sup>2</sup> independently is H, C<sub>1-6</sub>alkyl, or (CH<sub>2</sub>)<sub>0-6</sub>Phenyl;

R<sup>3</sup> is H, C<sub>1-6</sub>alkyl, CHO, COR<sup>1</sup>, or SO<sub>2</sub>R<sup>1</sup>;


R<sup>4</sup> is H or C<sub>1-6</sub>alkyl; and

5 Het is a heteroaryl group selected from thienyl, furanyl, pyrazolyl, imidazolyl, pyrrolyl, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridazolyl, pyrimidinyl, pyrazolyl, thiazolyl, pyridinyl, or tetrazolyl which are unsubstituted or  
10 substituted by C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, Cl, Br, F, I, NR<sup>3</sup>R<sup>4</sup>, CO<sub>2</sub>R<sup>2</sup>, CONR<sup>2</sup>R<sup>2</sup>, CN, or NO<sub>2</sub>;  
or a pharmaceutically acceptable salt thereof, provided that when X is H, Cl, Br, F, CF<sub>3</sub>, CH<sub>3</sub>, OCH<sub>3</sub>, OH, or  
15 OC(O)C<sub>1-6</sub>alkyl, A-Het is not -S(CH<sub>2</sub>)<sub>0-1</sub>-thienyl or -furanyl.

As used herein C<sub>1-6</sub>alkyl means straight or branched alkyl of one to six carbon atoms, C<sub>3-5</sub>alkenyl means a straight or branched chain alkenyl having from 3 to 5 carbon atoms, and "any accessible combination thereof" 20 means any combination of up to three substituents on the phenyl moiety that is available by chemical synthesis and is stable.

Formula (Ia) includes presently preferred Formula (I) compounds:

25



30

in which:

X is H, Cl, Br, F, I, CF<sub>3</sub>, C<sub>1-6</sub>alkyl, COR<sup>1</sup>, CO<sub>2</sub>R<sup>2</sup>, CONR<sup>2</sup>R<sup>2</sup>, CN, NO<sub>2</sub>, NR<sup>3</sup>R<sup>4</sup>, OR<sup>3</sup>, or SCF<sub>3</sub>;

R is H, C<sub>1-6</sub>alkyl, or C<sub>3-5</sub>alkenyl;

35 A is -OCO(CH<sub>2</sub>)<sub>1-4</sub>-, -OCH<sub>2</sub>CH=CH-, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>1-4</sub>-, -(CH<sub>2</sub>)<sub>0-6</sub>-, or -(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>m</sub>-, wherein n is 0-4 and m is 1-5, with the proviso that m and n taken together are no greater than 5;


Z is O or S;  
 each R<sup>1</sup> independently is C<sub>1-6</sub>alkyl or  
 (CH<sub>2</sub>)<sub>0-6</sub>phenyl;  
 each R<sup>2</sup> independently is H, C<sub>1-6</sub>alkyl, or  
 5 (CH<sub>2</sub>)<sub>0-6</sub>phenyl;  
 R<sup>3</sup> is H, C<sub>1-6</sub>alkyl, CHO, COR<sup>1</sup>, or SO<sub>2</sub>R<sup>1</sup>;  
 R<sup>4</sup> is H or C<sub>1-6</sub>alkyl; and  
 Het is a heteroaryl group selected from thienyl,  
 furanyl, pyrazolyl, imidazolyl, pyrrolyl, triazolyl,  
 10 oxazolyl, isoxazolyl, thiazolyl, pyridinyl, or  
 tetrazolyl, which are unsubstituted or substituted by  
 C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, Cl, Br, F, I, NR<sup>3</sup>R<sup>4</sup>, CO<sub>2</sub>R<sup>2</sup>,  
 CONR<sup>2</sup>R<sup>2</sup>, CN, or NO<sub>2</sub>;  
 or a pharmaceutically acceptable salt thereof, provided  
 15 that when X is H, Cl, Br, F, CF<sub>3</sub>, CH<sub>3</sub>, OCH<sub>3</sub>, OH, or  
 OC(O)C<sub>1-6</sub>alkyl, A-Het is not -S(CH<sub>2</sub>)<sub>0-1</sub>-thienyl or  
 -furanyl.

Preferred compounds are represented by Formula (Ia)  
 when:

20 X is Cl, Br, F, or I;  
 R is CH<sub>3</sub>; and  
 Het is pyrazolyl, furanyl, thienyl, triazolyl,  
 pyridinyl, or pyrrolyl with each heteroaryl group being  
 unsubstituted or substituted by Cl or CH<sub>3</sub>.

25

Scheme I



35


The benzazepines of formula (1) are described in  
 published references, such as *J. Med. Chem.*, 27:918-921  
 (1984), or can be obtained readily using known

- 7 -

procedures. According to Scheme I, the starting compounds of formula (1) are added to a suitable base, such as an alkali metal hydride, for example, sodium hydride, in a suitable organic solvent, such as 5 dimethylformamide. Thereafter, an appropriately substituted halide or sulfonate, such as 3-(bromomethyl)furan, 2-(3-chloro-1-propenyl)furan, or 2-(1H-pyrazol-1-yl)ethyl 4-methylbenzenesulfonate, is reacted with the above-generated intermediate to produce 10 Formula (I) compounds wherein A is  $-O(CH_2)_m-$  or  $-OCH_2CH=CH-$ .

Alternately, Formula (I) compounds wherein A is  $-O(CH_2)_2-$  are prepared by reacting the formula (1) benzazepine compounds with a suitable base, such as an 15 alkali metal hydride, in a suitable solvent, such as dimethylformamide, followed by reaction with an ester of a haloacetate, such as ethyl bromoacetate. The resulting (benzazepinyl)oxy acetate ester is reduced to the corresponding alcohol using an appropriate reducing 20 agent, such as lithium aluminum hydride, in an inert solvent, such as diethyl ether. Conversion of the alcohol to a suitable leaving group, such as a tosylate, or a mesylate, followed by displacement of the leaving group with an alkali metal salt of a heteroaryl group, 25 such as 1H-1,2,4-triazole sodium salt, in a suitable solvent, such as dimethylformamide, gives the Formula (I) compounds wherein A is  $-O(CH_2)_2-$ .

Scheme II



The benzazepines of formula (2) are known to the art (J. Med. Chem., 27:918-921 (1984)) or are synthesized by known procedures. According to Scheme II, the primary amine of formula (2) compounds is diazotized using, for 5 example, sodium nitrite in acetic acid, water, and sulfuric acid. Conversion to the corresponding cyano compounds of formula (3) is accomplished by reacting the diazonium salt with cyanide, for example, potassium cyanide. The carboxylic acid compounds of formula (4) 10 are prepared by reacting the cyano of the formula (3) compounds in the presence of barium hydroxide, in a suitable solvent, such as a mixture of ethanol and water. The resulting acids are reacted with a suitable base, such as an alkali metal hydride, such as sodium hydride, 15 in an appropriate solvent, such as dimethylformamide. Thereafter, reaction with an appropriately substituted halide, such as 4-chloro-1-(chloromethyl)-1H-pyrazole, gives formula (5) compounds, which are Formula (I) compounds wherein A is  $-\text{CO}_2(\text{CH}_2)_{1-4}-$ .


20 Formula (I) compounds wherein the heteroaryl group is directly attached to the phenyl portion of the benzazepine nucleus may be prepared from Formula (2) amine compounds. For example, the amine-substituted benzazepine compounds are reacted with 2,5-hexane-dione 25 or 2,5-dimethoxytetrahydrofuran in a suitable solvent, such as acetic acid or a mixture of acetic acid and toluene, at a temperature of about 80°C to about 120°C, preferably at about 110°C, to give pyrrole-substituted Formula (I) compounds.

30 Additionally, Formula (I) compounds wherein A is a methylene group may be prepared from formula (3) cyano compounds. The cyano group of the formula (3) benzazepines is reduced, for example, using lithium aluminum hydride, in an inert solvent, such as 35 tetrahydrofuran, at a temperature of about 20°C to about 75°C, preferably at about 70°C. The resulting methylamine compounds are then reacted with 2,5-hexane-dione or 2,5-dimethoxytetrahydrofuran, as described

hereinbefore, to give, for example, Formula (I) compounds wherein A is -CH<sub>2</sub>- and Het is a pyrrole moiety.

Scheme III

5



Scheme III illustrates the preparation of additional Formula (I) compounds. According to Scheme III, formula (3) cyano compounds are converted to the corresponding aldehyde derivatives of formula (6), for example using Raney® nickel in a suitable solvent, such as formic acid, at a temperature of about 35°C to about 100°C, preferably at about 100°C. The formula (7) hydroxymethyl benzazepines are prepared from the formula (6) aldehyde compounds by reductive methods, for example, using sodium borohydride in a suitable solvent, such as methanol, at a

temperature from about 0°C to about 35°C, preferably from about 5°C to about 24°C. Formula (8) benzazepines, which are Formula (I) compounds, are prepared from formula (7) benzazepines, using the methods described in Scheme I.

5 Scheme III also shows the preparation of Formula (I) compounds wherein A is -(CH<sub>2</sub>)<sub>3-5</sub>. According to Scheme III, formula (6) aldehyde compounds are reacted with a phosphorus ylide, such as triphenylphosphoranylideneacetaldehyde, in a suitable solvent, such as toluene, at a temperature of about 10 80°C to about 110°C, preferably at 110°C, or with an alkylphosphonic ester, such as triethyl phosphonoacetate, which is converted to a phosphonate carbanion in reaction with a suitable base, such as sodium hydride, in a suitable solvent, such as tetrahydrofuran, to give the corresponding 15 alkenyl derivatives, for example -CH=CH-CH=CH-CHO or -CH=CHCO<sub>2</sub>ethyl, respectively. The vinyl intermediates thus generated are reduced to the corresponding saturated analogs, for example by hydrogenation in the presence of a suitable catalyst, such as platinum oxide, in a suitable 20 solvent, such as ethanol. The terminal ester or formyl groups are reduced to the corresponding alcohol derivatives using standard reagents, for example, an ester-reducing agent, such as lithium aluminum hydride, or a formyl-reducing agent, such as sodium borohydride. The alcohols 25 are reacted with a halogenating agent, such as thionyl chloride, to give -(CH<sub>2</sub>)<sub>3-5</sub>halo benzazepines. Displacement of the halide by an alkali metal salt of a heteroaryl group, such as 1H-1,2,4-triazole sodium salt, gives Formula (I) compounds wherein A is -(CH<sub>2</sub>)<sub>3-5</sub>.

30 The pharmaceutically acceptable, nontoxic, acid addition salts having the utility of the free bases of Formula (I), are formed with inorganic or organic acids, by methods well known in the art. Representative examples of suitable acids are maleic, fumaric, benzoic, ascorbic, 35 pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanesulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic,

hydrochloric, hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric and nitric acids.

Because the compounds of Formula (I) are  $\alpha$ -adrenoceptor antagonists they are useful in treating cardiovascular diseases in which changes in vascular resistance are desirable, including hypertension, pulmonary hypertension, congestive heart failure, myocardial ischemia, and angina pectoris. Formula (I) compounds also are useful in treating peripheral vascular disease, benign prostatic hypertrophy, diabetes, glaucoma, ocular hypertension, obesity, disorders of gastrointestinal motility, including colonic spasm, irritable bowel syndrome, and constipation, impotence, and central nervous system disorders such as depression and senile dementia.

Additionally, the invented compounds are useful in treating diseases resulting from inappropriate platelet aggregation.

The  $\alpha$ -adrenoceptor activity of certain compounds of the present invention was determined using the following in vitro systems.

$\alpha_1$  adrenoceptor antagonist activity was determined using the rabbit aorta. Male New Zealand White rabbits (2-4 Kg) were euthanized by cervical concussion. A 4 cm portion of the thoracic aorta was removed and placed in a dish of cold (10°C) Krebs-Hensleit solution. The tissue was cleaned of fat and connective tissue and cut into segments of approximately 3 mm in length. These segments were suspended in 10 ml tissue baths via hangers constructed of 0.25 mm tungsten wire. One hanger was fixed to a support in the bath and the other was attached via silk thread to a force-displacement transducer.

Tissue segments were equilibrated for 2 hours prior to drug testing, during which time basal tension was maintained at 2 gm. Tissues were washed at 30 minute intervals during this equilibration period. The Krebs-Hensleit solution contained cocaine (6mM) to block neuronal uptake and propranolol (1mM) to block beta-adrenoceptors. Tissues were usually challenged once with norepinephrine

(0.1mM) during the equilibration period to check for viability.

A cumulative concentration-response curve to norepinephrine was obtained in each aortic segment.

5 Following washout of norepinephrine, the a adrenoceptor antagonist to be tested was added to the bath. After the tissue had been in contact with the antagonist for 30-60 minutes, the norepinephrine concentration response-curve was repeated in the presence of antagonist. The tissue was  
10 then washed again, and a tenfold higher concentration of antagonist added. Following equilibration (30-60 minutes), a third norepinephrine concentration-response curve was determined in the presence of the antagonist.

The receptor dissociation constant ( $K_B$ ) for the  
15 antagonist was determined using the relationship

$$K_B = \frac{\text{Antagonist Concentration}}{\text{Dose Ratio} - 1}$$

20 (Furchtgott, R. F., Handbook of Experimental Pharmacology, eds. Eichler, et al., pp. 283-335 (Springer 1972)). The  $K_B$  value obtained at each antagonist concentration was averaged to obtain a mean  $K_B$  for each experiment.

Alpha<sub>2</sub> adrenoceptor antagonist activity of the  
25 compounds was determined using the isolated, superfused guinea pig left atrium. Briefly, the heart is removed from a pentobarbital-anesthetized male guinea pig. The left atrium is separated, dissected free of extraneous tissue and mounted in a 2 ml superfusion chamber. The  
30 tissue is paced at 30 pulse/minute and the sympathetic nerves excited at 6 minute intervals by field stimulation. The response to nerve stimulation is measured as the difference in contractile force between the basal contraction and peak contraction following a nerve  
35 stimulation. A concentration-response curve for B-HT 920 (a known  $\alpha_2$  agonist) is prepared by administering increasing concentrations of B-HT 920 following each successive stimulation. The tissue then is superfused for thirty minutes with the  $\alpha$ -adrenoceptor antagonist to be

tested and the B-HT 920 concentration-effect curve is repeated in the presence of antagonist. Data are reported as  $K_B$ , defined above. Additional details of this test system are found in Hieble, J. P. and R. G. Pendleton,  
5 Arch. Pharmacol., 309:217-224 (1979).

Alpha<sub>3</sub> adrenoceptor antagonist receptor activity was determined using the dog saphenous vein (DSV) as the test system. This test system has been shown a suitable preparation in which to characterize postsynaptic  $\alpha_2$  ( $\alpha_3$ )  
10 adrenoceptors, Sullivan, A. T. and G. M. Drew, Arch. Pharmacol., 314:249-58 (1980). This test system is prepared by removing the lateral saphenous vein from an anesthetized dog and cutting the vein into segments of 4 mm in length. Segments are mounted as described for the  
15 isolated rabbit aorta.

The  $\alpha_3$  adrenoceptor antagonist activity of the compounds of interest is determined by measuring shifts in the dose-response curve of a specific agonist induced by the tested compounds. The  $\alpha_2$ ,  $\alpha_3$  agonist, B-HT 920, was  
20 used in testing the compounds listed in Table I.

Representative Formula (I) compounds which were tested using the above described *in vitro* test systems are listed in Table I. Each of the compounds tested was found to have antagonist activity at one or more of the  $\alpha$ -adrenoceptor  
25 subtypes.

Table I

6-chloro-9-(4-chloro-1H-pyrazol-1-ylmethoxy)-  
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
30 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-1-ylmethoxy)-1H-3-benzazepine;  
6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
35 6-chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-9-[3-(2-furanyl)-2-propenyl]oxy]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)-1H-3-benzazepine;  
5 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-pyrazol-1-yl)ethoxy]-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-  
10 pyridinylmethoxy)-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-1H-3-benzazepine;  
6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-  
15 methyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-  
carbonyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-  
y1)-1H-3-benzazepine;  
6-chloro-9-(2,5-dimethyl-1H-pyrrol-1-yl)-2,3,4,5-  
20 tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-  
ylmethyl)-1H-3-benzazepine;  
6-chloro-9-[3-(4-chloro-1H-pyrazol-1-yl)propyl]-  
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine; and  
25 6-chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)pentyl]-  
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine; or a  
pharmaceutically acceptable salt thereof.

The antihypertensive activity of certain compounds of the present invention was determined using the 30 spontaneously hypertensive rat model. The details of this in vivo test are found in Roesler, J. M., et al., J. Pharmacol. Exp. Ther., 236:1-7 (1986).

Novel pharmaceutical compositions are obtained when the compounds are incorporated with pharmaceutical carriers 35 into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers can be employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose,

talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as 5 glycercyl monostearate or glycercyl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, 10 emulsion, soft gelatin capsule, sterile injectable liquid, or an aqueous or nonaqueous liquid suspension or solution.

The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating and compressing, when 15 necessary, for tablet forms, or mixing, filling, and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.

Doses of the present compounds in pharmaceutical dosage units will be an efficacious, nontoxic quantity 20 selected from the range of 0.01-100 mg/kg of active compound, preferably 0.1-50 mg/kg. The selected dose is administered to a human patient in need of treatment from 1-6 times daily, orally, rectally, topically, by inhalation, or injection, or continuously by infusion. 25 Oral administration, however, is preferred because it is more convenient for the patient.

The following examples are illustrative of preparation of Formula (I) compounds. The examples are not intended to limit the scope of the invention as defined hereinabove and 30 as claimed below.

Example 1

35 6-Chloro-9-(4-chloro-1H-pyrazol-1-ylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine

A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-ol, (633 mg, 3 mmol, J. Med. Chem., 27,

918 (1984)) in dry dimethylformamide (10 ml) was treated with sodium hydride (50% dispersion in mineral oil, 3.9 mmol), stirred for 10 minutes and treated with a solution of 4-chloro-1-(chloromethyl)-1H-pyrazole (485 mg, 3.1 mmol) in dimethylformamide (5 ml). The mixture was heated to 50°C for 30 minutes, poured into ice water, basified with 10% sodium hydroxide and extracted with ethyl acetate. The organic phase was washed with brine, dried with magnesium sulfate and concentrated. The residue was treated with hydrogen chloride in ethanol-ethyl ether to give 275 mg (26%) of 6-chloro-9-(4-chloro-1H-pyrazol-1-ylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine hydrochloride (acetone); mp 174-175°C.

15

Example 26-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-1-ylmethoxy)-1H-3-benzazepine

20 Using the general procedure of Example 1, replacing 4-chloro-1-(chloromethyl)-1H-pyrazole with 1-(chloromethyl)-1H-pyrazole gave, after chromatography on silica gel eluted with a methanol-methylene chloride gradient, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-1-ylmethoxy)-1H-3-benzazepine; mp 69-71.5°C .

Examples 3-106-Chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine6-Chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine6-Chloro-9-[3-(2-furanyl)-2-propenyl]tetrahydro-3-methyl-1H-3-benzazepine

6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)-1H-3-benzazepine

5       6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)-1H-3-benzazepine

6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-(1H-pyrazol-1-yl)ethoxy)-1H-3-benzazepine

10      6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)-1H-3-benzazepine

6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)-1H-3-benzazepine

15      Using the general procedure of Example 2, replacing 1-(chloromethyl)-1H-pyrazole with 2-(chloromethyl)furan, 3-(bromomethyl)furan, 2-(3-chloro-1-propenyl)furan, 2-(bromomethyl)thiophene, 3-(bromomethyl)thiophene, 2-(1H-pyrazol-1-yl)ethyl 4-methylbenzenesulfonate, 1-(chloromethyl)-1H-1,2,4-triazole, and 4-(chloromethyl)pyridine hydrochloride gave:

25      6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine maleate; mp 168-173.5°C,

6-chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine maleate; mp 181-183°C,

30      6-chloro-9-[3-(2-furanyl)-2-propenyl]oxy]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine maleate; mp 149-153.5°C,

35      6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)-1H-3-benzazepine maleate; 196.5-199.5°C,

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)-1H-3-benzazepine maleate; mp 195.5-198.5°C,

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-pyrazol-1-yl)ethoxy]-1H-3-benzazepine hydrochloride;  
mp 98-180°C,

5

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)-1H-3-benzazepine hydrochloride;  
mp 82-92.5°C, and

10 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)-1H-3-benzazepine dihydrochloride (ethanolethyl acetate); mp 222°C (dec).

Example 11

15

6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-1H-3-benzazepine

A 35% dispersion of potassium hydride in mineral oil (2.6 g, 23 mmol) in dimethylformamide (40 ml) was stirred and treated with 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-ol (4.0 g, 19 mmol), stirred for 20 minutes, treated with ethyl bromoacetate (3.8 g, 23 mmol) and stirred for 72 hours. The mixture was concentrated, partitioned between water and methylene chloride and the organic phase was washed, dried with magnesium sulfate and concentrated. The residue was chromatographed on silica gel eluted with methanol-methylene chloride (8:92) to give 4.3 g of ethyl [(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]acetate.

Lithium aluminum hydride (1.53 g, 40 mmol) in ethyl ether (80 ml) was stirred, heated to reflux and treated with a solution of ethyl [(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]acetate (4.0 g, 13.5 mmol) in ethyl ether (60 ml). The mixture was stirred at reflux for 3.5 hours, cooled, and carefully treated with water (1.5 ml), 10% sodium hydroxide (4.5 ml) and water

(1.5 ml). The mixture was filtered and the filtrate dried with magnesium sulfate and concentrated to give 3,2 g (91%) of [(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]ethanol.

5

A solution of [(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]ethanol (0.375 g, 1.5 mmol) in pyridine (5 ml) was stirred at 5°C, treated with 4-methylbenzenesulfonyl chloride (0.56 g, 3 mmol) and 10 stored in a freezer for 16 hours. The mixture was poured into water and extracted with ethyl ether. The organic phase was washed and concentrated under high vacuum to give 0.5 g of [(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]ethanol 4-methylbenzenesulfonate.

15

Following the general procedure of Example 2, [(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]ethanol 4-methylbenzenesulfonate was heated with one equivalent of 1H-1,2,4-triazole sodium salt (prepared 20 from 1H-1,2,4-triazole and sodium hydride in dimethylformamide) at 65°C for 30 minutes to give 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-1H-3-benzazepine hydrochloride; mp 204-211°C.

25

Example 12

6-Chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)methyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine

30

A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-amine, (10 g, 47.5 mmol) in acetic acid (34 ml) and water (20 ml) was stirred, treated with sulfuric acid (7.5 ml), cooled to 5°C and treated with a 35 solution of sodium nitrite (3.65 g, 53 mmol) in water (7.5 ml) added below the surface over 20 minutes. The mixture was added dropwise under the surface of a stirred mixture prepared from cupric sulfate pentahydrate (14.2

g, 57 mmol) in water (35 ml), potassium cyanide (15.4 g, 240 mmol), ice (24 g), sodium bicarbonate (31.8 g, 380 mmol) in water (36 ml) and toluene (35 ml) at 50-55°C. The mixture was stirred for 15 minutes at 50°C and for 1 5 hour at 25°C, treated with a solution of sodium bicarbonate (70 g) in water (700 ml) to pH 8 and then with 10% sodium hydroxide (300 ml). The mixture was extracted with ethyl acetate and the organic phase was washed with aqueous sodium hydroxide and brine, dried 10 with magnesium sulfate and concentrated. The residual oil was treated with ethereal hydrogen chloride to give 8.3 g (68%) of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carbonitrile; mp 288-290°C.

15 A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carbonitrile (3.1 g, 14 mmol) in 90% formic acid (40 ml) was treated with Raney® nickel (3.1 g), stirred and heated to reflux for 3 hours. Additional Raney® nickel (17 g) and 90% formic acid (85 ml) were added 20 over the next 12 hours and the mixture was stirred for an additional 3 hours. The mixture was cooled, filtered and the filter cake washed with 45% formic acid. The filtrate was concentrated, basified with 10% sodium hydroxide, extracted with ethyl acetate and the organic phase was 25 washed, dried and concentrated to give 3 g of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carboxaldehyde.

30 A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carboxaldehyde (3.07 g, 13.8 mmol) in methanol (35 ml) was cooled to 5°C and treated with sodium borohydride (3.07 g, 81 mmol). The mixture was stirred for 15 minutes at 5°C and for 45 minutes at 25°C. The mixture was cooled and carefully treated with dilute 35 hydrochloric acid. The mixture was diluted with brine, basified with 10% sodium hydroxide and extracted with ethyl acetate. The organic phase was dried, concentrated and the residue chromatographed on silica gel eluted with

a gradient of methanol-methylene chloride (5:95-9:91) to give 1.45 g (47%) of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-methanol; mp 136.5-140°C.

5       Using the general procedure of Example 1, replacing 9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-ol with 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-methanol gave, after chromatography on silica gel eluted with methanol-methylene chloride (4:96), 0.3 g (40%) of  
10 6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)methyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine hydrochloride; mp 168-171°C.

Example 13

15

6-Chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)carbonyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine

20       A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carbonitrile, prepared as in Example 12, (1.5 g, 6.8 mmol) in ethanol (25 ml) was treated with barium hydroxide octahydrate (2.6 g, 8.1 mmol) and water (25 ml) and heated to reflux for 94 hours. The mixture was cooled, diluted with water, ethanol and methanol,  
25       saturated with carbon dioxide and filtered. The filtrate was treated with Dry Ice to pH 5-6 and filtered. The filtrate was concentrated and extracted with ethyl acetate-ethyl ether and ethyl ether. The aqueous phase was treated with toluene, concentrated and the residue  
30       triturated with ethyl ether to give 9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine-6-carboxylic acid.

35       Using the general procedure of Example 1, replacing 9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-ol with 9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine-6-carboxylic acid gave, after chromatography on silica gel eluted with methanol-methylene chloride (3:97), 94 mg (10%) of 6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)carbonyl]-

2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine maleate;  
mp 144-149°C.

Example 14

5

6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-yl)-1H-3-benzazepine

A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-amine (633 mg, 3 mmol) in acetic acid (6 ml) was treated with 2,5-dimethoxytetrahydrofuran (396 mg, 3 mmol) and stirred at 110°C for 1.5 hours. The mixture was poured into ice, basified with 10% sodium hydroxide and extracted with ethyl acetate. The organic phase was dried, concentrated and treated with hydrogen chloride to give 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-yl)-1H-3-benzazepine hydrochloride (methanol-acetonitrile); mp 262-264°C.

20

Example 15

6-Chloro-9-(2,5-dimethyl-1H-pyrrol-1-yl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine

25 Using the general procedure of Example 40, 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-amine (420 mg, 2.7 mmol) in acetic acid (6 ml) and toluene (6 ml) was treated with 2,5-hexanedione (300 mg, 2.7 mmol) and heated to reflux for 1 hour to give 6-chloro-9-(2,5-dimethyl-1H-pyrrol-1-yl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine (acetonitrile); mp 268-270°C.

Example 16

35 6-Chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-ylmethyl)-1H-3-benzazepine

A suspension of lithium aluminum hydride (1.14 g, 30 mmol) in tetrahydrofuran (20 ml) was stirred and treated with a solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carbonitrile, prepared as in Example 5 12, (1.5 g, 6.8 mmol) in tetrahydrofuran (20 ml) and heated to reflux for 3 hours. The mixture was cooled and treated with water (1.14 ml), 10% sodium hydroxide (1.14 ml) and water (1.14 ml), diluted with tetrahydrofuran (100 ml), stirred for 1 hour, filtered and concentrated 10 to give 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-methanamine.

A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-methanamine (0.75 g, 3.4 mmol) in 15 acetic acid (6.5 ml) was treated with 2,5-dimethoxy-tetrahydrofuran (0.44 ml, 3.4 mmol) and heated to 115°C for 1 hour. The mixture was quenched with ice water, basified with 20% sodium hydroxide and extracted with 20 ethyl acetate. The organic phase was washed, dried and concentrated. The residue was triturated with ethyl ether and the residue chromatographed on silica gel eluted with methanol-methylene chloride (3:97) to give 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-ylmethyl)-1H-3-benzazepine hydrochloride; mp 219-223°C.

25

Example 17

6-Chloro-9-[3-(4-chloro-1H-pyrazol-1-yl)propyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine

30

A solution of triethyl phosphonoacetate (1.9 g, 8.6 mmol) in tetrahydrofuran (200 ml) was stirred and treated with a 50% dispersion of sodium hydride in mineral oil (0.45 g, 9.4 mmol), stirred for 15 minutes and treated 35 with a solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carboxaldehyde, prepared as in Example 12, (2.2 g, 9.0 mmol) in tetrahydrofuran (270 ml). The mixture was stirred for 16 hours, concentrated, dissolved

in ethyl ether and washed with water and brine. The organic phase was dried with magnesium sulfate and concentrated to give 2.6 g of ethyl (E)-3-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)-2-5 propenoate.

A solution of ethyl (E)-3-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)-2-propenoate (2.6 g, 8.9 mmol) in ethanol (150 ml) was treated with 10 concentrated hydrochloric acid (18 drops) and platinum oxide (0.11 g) and shaken under hydrogen (40 psi) for 2 hours, filtered and concentrated. The residue was partitioned between cooled ethyl acetate-ethyl ether (3:1) (300 ml) and 5% sodium bicarbonate. The organic 15 phase was washed with water and brine, dried with magnesium sulfate and concentrated to give 2.5 g (96%) of ethyl 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-propanoate.

20 A suspension of lithium aluminum hydride (0.55 g, 14.6 mmol) in tetrahydrofuran (20 ml) was stirred, heated to reflux and treated with a solution of ethyl 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-propanoate (2.1 g, 7 mmol) in tetrahydrofuran (25 ml). 25 The mixture was stirred at reflux for 3 hours, cooled and carefully treated with water (1.65 ml) and 10% sodium hydroxide (0.55 ml). The mixture was stirred at 25°C, filtered and the filtrate was concentrated. The residue was dissolved in ethyl acetate-ethyl ether (4:1) (160 ml) 30 and washed with water, 5% sodium hydroxide and water, filtered, dried with magnesium sulfate and concentrated. The residue was partitioned between ethyl acetate-ethyl ether (2:1) and 3N hydrochloric acid. The aqueous phase was washed with ethyl ether, basified with aqueous sodium 35 hydroxide and extracted with ethyl acetate-ethyl ether (2:1). The organic phase was washed with water and brine, dried with magnesium sulfate and concentrated. The residue was dissolved in ethyl ether and treated with

ethereal hydrogen chloride to give 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-propanol hydrochloride; mp 218.5-223.5°C.

5 A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-propanol (0.8 g, 3 mmol) in methylene chloride (30 ml) was stirred at 5°C and treated with thionyl chloride (40 ml). The mixture was stirred for 10 minutes at 5°C, 15 minutes at 25°C, 3 hours at 55°C and 10 16 hours at 25°C. The mixture was concentrated to give 0.96 g of 6-chloro-9-(3-chloropropyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine hydrochloride.

15 Using the general procedure of Example 11, replacing [(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]ethanol 4-methylbenzenesulfonate with 6-chloro-9-(3-chloropropyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine and 1H-1,2,4-triazole sodium salt with 4-chloro-1H-pyrazole gave 0.33 g (60%) of 6-chloro-9-[3-(4-chloro-1H-pyrazol-1-yl)propyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine hydrochloride; mp 142.5-145°C.

#### Example 18

25 6-Chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)pentyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine

A solution of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-carboxaldehyde, prepared as in Example 30 12, (2.2 g, 10 mmol) in toluene (15 ml) was treated with triphenylphosphoranylideneacetaldehyde (4.4 g, 14 mmol) and stirred at 100°C for 24 hours. The mixture was concentrated and the residue was triturated with ethyl ether-petroleum ether (4:1) and the supernatant 35 concentrated to give 3 g of 5-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)-2,4-pentadienal.

A solution of 5-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)-2,4-pentadienal (3 g) in ethanol (100 ml) and platinum oxide was shaken under hydrogen (50 psi) for 2 hours, filtered, concentrated and 5 the residue chromatographed on silica gel eluted with a gradient of methanol-methylene chloride (3:97-7:93) to give 0.5 g of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-pentanal.

10 Using the general procedure of Example 12, replacing 9-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-6-carboxaldehyde with 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-pentanal gave 0.33 g (64%) of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-pentanol.

15 Using the general procedure of Example 43, replacing 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-propanol with 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine-6-pentanol gave 6-chloro-9-(5-chloropentyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine hydrochloride.

20 Using the general procedure of Example 43, replacing 6-chloro-9-(3-chloropropyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine with 6-chloro-9-(5-chloropentyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine gave 52 mg (13 %) of 6-chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)pentyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine 25 hydrochloride; mp 158-161°C.

#### EXAMPLE 19

An oral dosage form for administering the presently invented compounds is produced by screening, mixing, and 30 filling into a hard gelatin capsule ingredients in the proportions shown in Table II, below.

Table II

<u>Ingredients</u>	<u>Amounts</u>
6-chloro-9- (3-furanylmethoxy)-	50 mg
2,3,4,5-tetrahydro-3-methyl-1H-3-	
benzazepine	
magnesium stearate	5 mg
lactose	75 mg

EXAMPLE 20

5 The sucrose, calcium sulfate dihydrate and Formula (I) compound shown in Table III below, are mixed and granulated with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

10

Table III

<u>Ingredients</u>	<u>Amounts</u>
6-chloro-2,3,4,5,-tetrahydro-3-	100 mg
methyl-9- (1H-pyrazol-1-ylmethoxy)-	
1H-3-benzazepine	
calcium sulfate dihydrate	150 mg
sucrose	20 mg
starch	10 mg
talc	5 mg
stearic acid	3 mg

EXAMPLE 21


15 6-Chloro-9- (3-furanylmethoxy) 2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine 75 mg, is dispersed in 25 ml of normal saline to prepare an injectable preparation.

20 While the preferred embodiments of the invention are illustrated by the above, the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

What is claimed is:

1. A compound having the formula:

5



10 in which:

X is H, Cl, Br, F, I, CF<sub>3</sub>, C<sub>1</sub>-6alkyl, COR<sup>1</sup>, CO<sub>2</sub>R<sup>2</sup>, CONR<sup>2</sup>R<sup>2</sup>, CN, NO<sub>2</sub>, NR<sup>3</sup>R<sup>4</sup>, OR<sup>3</sup>, SR<sup>1</sup>, SCF<sub>3</sub>, or any accessible combination thereof up to three substituents;

R is H, C<sub>1</sub>-6alkyl, or C<sub>3</sub>-5alkenyl;

15 A is -OCO(CH<sub>2</sub>)<sub>1-4</sub>-, -OCH<sub>2</sub>CH=CH-, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>1-4</sub>-, -(CH<sub>2</sub>)<sub>0-6</sub>-, or -(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>m</sub>-, wherein n is 0-4 and m is 1-5, with the proviso that m and n taken together are no greater than 5;

Z is O or S;

20 each R<sup>1</sup> independently is C<sub>1</sub>-6alkyl or (CH<sub>2</sub>)<sub>0-6</sub>phenyl;

each R<sup>2</sup> independently is H, C<sub>1</sub>-6alkyl, or (CH<sub>2</sub>)<sub>0-6</sub>phenyl;

R<sup>3</sup> is H, C<sub>1</sub>-6alkyl, CHO, COR<sup>1</sup>, or SO<sub>2</sub>R<sup>1</sup>;

25 R<sup>4</sup> is H or C<sub>1</sub>-6alkyl; and

Het is a heteroaryl group selected from thienyl, furanyl, pyrazolyl, imidazolyl, pyrrolyl, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridazolyl, pyrimidinyl, pyrazolyl, thiazolyl,


30 pyridinyl, or tetrazolyl which are unsubstituted or substituted by C<sub>1</sub>-6alkyl, C<sub>1</sub>-6alkoxy, Cl, Br, F, I, NR<sup>3</sup>R<sup>4</sup>, CO<sub>2</sub>R<sup>2</sup>, CONR<sup>2</sup>R<sup>2</sup>, CN, or NO<sub>2</sub>;

or a pharmaceutically acceptable salt thereof, provided that when X is H, Cl, Br, F, CF<sub>3</sub>, CH<sub>3</sub>, OCH<sub>3</sub>, OH, or

35 OC(O)C<sub>1</sub>-6alkyl, A-Het is not -S(CH<sub>2</sub>)<sub>0-1</sub>-thienyl or -furanyl.

2. A compound of claim 1 having the formula:

5



in which:

X is H, Cl, Br, F, I,  $\text{CF}_3$ ,  $\text{C}_1\text{-6alkyl}$ ,  $\text{COR}^1$ ,  $\text{CO}_2\text{R}^2$ ,  
 10  $\text{CONR}^2\text{R}^2$ , CN,  $\text{NO}_2$ ,  $\text{NR}^3\text{R}^4$ ,  $\text{OR}^3$ ,  $\text{SR}^1$ , or  $\text{SCF}_3$ ,  
 R is H,  $\text{C}_1\text{-6alkyl}$ , or  $\text{C}_3\text{-5alkenyl}$ ;  
 A is  $-\text{OCO}(\text{CH}_2)_{1-4}-$ ,  $-\text{OCH}_2\text{CH}=\text{CH}-$ ,  $-\text{CO}_2(\text{CH}_2)_{1-4}-$ ,  
 $-(\text{CH}_2)_{0-6}-$ , or  $-(\text{CH}_2)_n\text{Z}(\text{CH}_2)_m-$ , wherein n is 0-4 and m is  
 15 1-5, with the proviso that m and n taken together are no  
 greater than 5;  
 Z is O or S;  
 each  $\text{R}^1$  independently is  $\text{C}_1\text{-6alkyl}$  or  
 $(\text{CH}_2)_{0-6}\text{phenyl}$ ;  
 each  $\text{R}^2$  independently is H,  $\text{C}_1\text{-6alkyl}$ , or  
 20  $(\text{CH}_2)_{0-6}\text{phenyl}$ ;  
 $\text{R}^3$  is H,  $\text{C}_1\text{-6alkyl}$ , CHO,  $\text{COR}^1$ , or  $\text{SO}_2\text{R}^1$ ;  
 $\text{R}^4$  is H or  $\text{C}_1\text{-6alkyl}$ ; and  
 Het is a heteroaryl group selected from thiienyl,  
 furanyl, pyrazolyl, imidazolyl, pyrrolyl, triazolyl,  
 25 oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl,  
 pyridazolyl, pyrimidinyl, pyrazolyl, thiazolyl,  
 pyridinyl, or tetrazolyl which are unsubstituted or  
 substituted by  $\text{C}_1\text{-6alkyl}$ ,  $\text{C}_1\text{-6alkoxy}$ , Cl, Br, F, I,  
 $\text{NR}^3\text{R}^4$ ,  $\text{CO}_2\text{R}^2$ ,  $\text{CONR}^2\text{R}^2$ , CN, or  $\text{NO}_2$ ;  
 30 or a pharmaceutically acceptable salt thereof, provided  
 that when X is H, Cl, Br, F,  $\text{CF}_3$ ,  $\text{CH}_3$ ,  $\text{OCH}_3$ , OH, or  
 $\text{OC}(\text{O})\text{C}_1\text{-6alkyl}$ , A-Het is not  $-\text{S}(\text{CH}_2)_{0-1}\text{-thienyl}$  or  
 $-\text{furanyl}$ .  
 35 3. A compound of claim 2 wherein X is Cl, Br, F,  
 or I.

4. A compound of claim 3 wherein Het is pyrazolyl, furanyl, thienyl, triazolyl, pyridinyl, or pyrrolyl with each heteroaryl group being unsubstituted or substituted by Cl or CH<sub>3</sub>.

5

5. A compound of claim 4 wherein R is CH<sub>3</sub>.

6. A compound of claim 5 which is 6-chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine or a pharmaceutically acceptable salt thereof.

7. A compound of claim 5 which is:  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-1-ylmethoxy)-1H-3-benzazepine;  
6-chloro-9-(4-chloro-1H-pyrazol-1-ylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-9-[3-(2-furanyl)-2-propenyl]oxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-pyrazol-1-yl)ethoxy]-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)-1H-3-benzazepine;  
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-1H-3-benzazepine;  
6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-methyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;  
6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-carbonyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-yl)-1H-3-benzazepine;

6-chloro-9-(2,5-dimethyl-1H-pyrrol-1-yl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

5 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-ylmethyl)-1H-3-benzazepine;

6-chloro-9-[3-(4-chloro-1H-pyrazol-1-yl)propyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine; or

6-chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)pentyl]-10 2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of claim 1 and a suitable pharmaceutical carrier.

9. A pharmaceutical composition of claim 8 wherein the compound is 6-chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.

20 10. A pharmaceutical composition of claim 8 wherein the compound is:

6-chloro-9-(4-chloro-1H-pyrazol-1-ylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

25 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-1-ylmethoxy)-1H-3-benzazepine;

6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

30 6-chloro-9-[3-(2-furanyl)-2-propenyl]oxy]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)-1H-3-benzazepine;

35 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-pyrazol-1-yl)ethoxy]-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-1H-3-benzazepine;

5 6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-methyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-carbonyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-yl)-1H-3-benzazepine;

10 6-chloro-9-(2,5-dimethyl-1H-pyrrol-1-yl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-ylmethyl)-1H-3-benzazepine;

15 6-chloro-9-[3-(4-chloro-1H-pyrazol-1-yl)propyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine; or

6-chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)pentyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.

20 11. A method of antagonizing  $\alpha$ -adrenergic receptors in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

25 12. A method of claim 11 wherein the compound is 6-chloro-9-(3-furanylmethoxy)2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.

13. A method of claim 11 wherein the compound is:

30 6-chloro-9-(4-chloro-1H-pyrazol-1-ylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-1-ylmethoxy)-1H-3-benzazepine;

35 6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-9-[3-(2-furanyl)-2-propenyl]oxy]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)-1H-3-benzazepine;

5 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-pyrazol-1-yl)ethoxy]-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)-1H-3-benzazepine;

10 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-1H-3-benzazepine;

6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-methyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

15 6-chloro-9-[(4-chloro-1H-pyrazol-1-ylmethoxy)-carbonyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-yl)-1H-3-benzazepine;

6-chloro-9-(2,5-dimethyl-1H-pyrrol-1-yl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine;

20 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrrol-1-ylmethyl)-1H-3-benzazepine;

6-chloro-9-[3-(4-chloro-1H-pyrazol-1-yl)propyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine; or

25 6-chloro-9-[5-(4-chloro-1H-pyrazol-1-yl)pentyl]-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.

14. A method of treating hypertension in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

15. A method of treating congestive heart failure in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

16. A method of treating peripheral vascular disease in mammals which comprises administering to a

subject in need thereof an effective amount of a compound of claim 1.

17. A method of treating benign prostatic hypertrophy in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/06538

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(S) :C07D 223/16,239/26,A61K 31/55  
US CL :514/213;540/594

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/213;540/594

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE-STRUCTURE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A, 4,265,890 HOLDEN ET AL., 05 MAY 1981, See example 18.	1-8
A	US,A, 4,469,634 (DEMARINIS), 04 SEPTEMBER 1984, See entire document.	1-14
A	US,A, 4,683,229 (DEMARINIS, ET AL), 28 JULY 1987, See entire document.	1-14
A	DEMARINIS, ET AL. J. MED CHEM. 1984 27, 918-921 "Development of an Affinity Ligand for Purification of $\alpha_2$ -Adrenoceptors from Human Platelet membranes. See entire document.	1-14



Further documents are listed in the continuation of Box C.



See patent family annex.

•	Special categories of cited documents:	“T”	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
“A”	document defining the general state of the art which is not considered to be part of particular relevance	“X”	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
“E”	earlier document published on or after the international filing date	“Y”	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
“L”	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“&”	document member of the same patent family
“O”	document referring to an oral disclosure, use, exhibition or other means		
“P”	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 NOVEMBER 1992

Date of mailing of the international search report

09 DEC 1992

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer *Edward C. Ward*

EDWARD C. WARD

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/06538

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Timmermans, et al. J. Med. Chem 1982, 25 pp. 1385-1401" x <sub>2</sub> Adrenoceptors: Classification, Localization, Mechanisms, and targets for Drugs" see entire document.	1-14
X	US,A, 4,233,217 (SHETTY), 11 NOVEMBER 1992, see col. 43, line 20-30.	1-3 and 8

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*